Ericksen Scott D sold $305K of ILMN

Ericksen Scott D (VP, Chief Accounting Officer) sold 2,000 shares of ILLUMINA, INC. (ILMN) at an average of $152.58 ($150.10–$160.00, $0.31M total) across 2 trades over 2026-05-28 to 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ericksen Scott D
Published Jun 1, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
medium confidence
Mentioned
$ILMN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishLow
01

Why it matters

The disclosure provides fresh data on insider activity, but the transaction size is modest.

02

Market read

New insider sale information; limited trading relevance.

03

What to watch

Insider still retains ~14,000 shares, representing a small stake.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Illumina filed a Form 4 reporting a 10b5‑1 sale by its VP of Accounting.

Company-level read

Ticker impact

$ILMNBearishMedium confidence
Context

Form 4 shows VP and CFO sold 2,000 shares for $305K via a 10b5‑1 plan.

Expected impact

likely slight pressure as market prices in the insider sell

Evidence & confidence

Sale size is modest relative to float, but a C‑suite insider selling can prompt short‑term weakness.

Market effects

Minimal impact on the broader semiconductor sector.

U.S. market only; no regional ripple.

Low; isolated to Illumina.

Counterpoint

The sale could be routine under a pre‑arranged plan, not a bearish signal.

Key entities

  • Ericksen Scott D

    VP, Chief Accounting Officer at Illumina

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.